Novartis puts brakes on price hikes, bowing to U.S. pressure

Bolstered by a strong second-quarter, CEO Vas Narasimhan said he expects Novartis to hit the top of its 2018 sales guidance despite joining rival Pfizer in freezing U.S. drug prices for the rest of the year.

…read more

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Source:: Reuters – Business News